Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Starling

Showing results (151-160 of 155) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 155 results.
Molecular Cancer Therapeutics|December 21, 2013
Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activityRobert M Campbell, Bryan D Anderson, Nathan A Brooks, et al.
Investigational New Drugs|March 2, 2011
Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft modelTimothy P Burkholder, Joshua R Clayton, Mark E Rempala, et al.
Molecular Cancer Therapeutics|April 2, 2014
A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor modelsTinggui Yin, Maria J Lallena, Emiko L Kreklau, et al.
Cancer Cell|September 8, 2015
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant CancersSheng-Bin Peng, James R Henry, Michael D Kaufman, et al.
Journal of Medicinal Chemistry|May 13, 2015
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cellsJames R Henry, Michael D Kaufman, Sheng-Bin Peng, et al.
Pageof 16

Showing results (151-160 of 155) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 155 results.
Molecular Cancer Therapeutics|December 21, 2013
Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activityRobert M Campbell, Bryan D Anderson, Nathan A Brooks, et al.
Investigational New Drugs|March 2, 2011
Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft modelTimothy P Burkholder, Joshua R Clayton, Mark E Rempala, et al.
Molecular Cancer Therapeutics|April 2, 2014
A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor modelsTinggui Yin, Maria J Lallena, Emiko L Kreklau, et al.
Cancer Cell|September 8, 2015
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant CancersSheng-Bin Peng, James R Henry, Michael D Kaufman, et al.
Journal of Medicinal Chemistry|May 13, 2015
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cellsJames R Henry, Michael D Kaufman, Sheng-Bin Peng, et al.
Pageof 16